A detailed history of Virtu Financial LLC transactions in Argenx Se stock. As of the latest transaction made, Virtu Financial LLC holds 1,218 shares of ARGX stock, worth $687,232. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,218
Holding current value
$687,232
% of portfolio
0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$356.01 - $451.55 $433,620 - $549,987
1,218 New
1,218 $524,000
Q4 2023

Feb 26, 2024

SELL
$338.91 - $506.01 $307,391 - $458,951
-907 Reduced 56.62%
695 $264,000
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $591,698 - $878,584
1,602 New
1,602 $787,000
Q1 2023

May 01, 2023

BUY
$334.23 - $403.65 $833,569 - $1.01 Million
2,494 New
2,494 $929,000
Q3 2022

Nov 07, 2022

BUY
$343.2 - $395.75 $1.06 Million - $1.22 Million
3,076 New
3,076 $1.09 Million
Q2 2022

Aug 09, 2022

SELL
$269.58 - $378.88 $188,706 - $265,216
-700 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$254.45 - $351.06 $178,115 - $245,742
700 New
700 $221,000
Q2 2021

Sep 17, 2021

SELL
$257.11 - $319.92 $485,423 - $604,008
-1,888 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$268.3 - $380.31 $506,550 - $718,025
1,888 New
1,888 $520,000
Q3 2020

Dec 11, 2020

SELL
$215.51 - $272.51 $284,257 - $359,440
-1,319 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$127.44 - $232.72 $168,093 - $306,957
1,319 New
1,319 $297,000
Q2 2019

Aug 13, 2019

SELL
$115.0 - $141.58 $199,870 - $246,066
-1,738 Closed
0 $0
Q1 2019

Apr 12, 2019

SELL
$98.85 - $134.59 $357,738 - $487,081
-3,619 Reduced 67.56%
1,738 $217,000
Q1 2018

May 14, 2018

BUY
$56.95 - $85.19 $305,081 - $456,362
5,357 New
5,357 $431,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.